DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting

DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General


Meeting

Shareholders approve all proposed resolutions

DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today held its Ordinary and Extraordinary General Meeting, which was chaired by Dr. Pierre-Henri Benhamou, Chairman & Chief Executive Officer of DBV Technologies.

At the General Meeting, the Company's shareholders approved all resolutions submitted by the Board of Directors. These resolutions are posted on the Investor Relations section of the Company's website,
http://www.dbv-technologies.com/en/investor-relations
.

About DBV Technologies 


DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.


DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website:
www.dbv-technologies.com

DBV Technologies Contact


Sara Blum Sherman


Director, Investor Relations


+1 212-271-0740


sara.sherman@dbv-technologies.com

Media Contact


Andrea Fassacesia, Weber Shandwick


+1 212-445-8144


afassacesia@webershandwick.com

Media Contact Europe


Caroline Carmagnol, Alize RP, Relations Presse


+33 (0)6 64 18 99 59 


caroline@alizerp.com